A unicenter real-world study of the correlation factors for complete clinical response in idiopathic inflammatory myopathies
OBJECTIVE: To investigate the correlation factors of complete clinical response in idiopathic inflammatory myopathies (IIMs) patients receiving conventional treatment.
METHODS: Patients diagnosed with IIMs hospitalized in Peking University People's Hospital from January 2000 to June 2023 were included. The correlation factors of complete clinical response to conventional treatment were identified by analyzing the clinical characteristics, laboratory features, peripheral blood lymphocytes, immunological indicators, and therapeutic drugs.
RESULTS: Among the 635 patients included, 518 patients finished the follow-up, with an average time of 36.8 months. The total complete clinical response rate of IIMs was 50.0% (259/518). The complete clinical response rate of dermatomyositis (DM), anti-synthetase syndrome (ASS) and immune-mediated necrotizing myopathy (IMNM) were 53.5%, 48.9% and 39.0%, respectively. Fever (P=0.002) and rapid progressive interstitial lung disease (RP-ILD) (P=0.014) were observed much more frequently in non-complete clinical response group than in complete clinical response group. The aspartate transaminase (AST), lactate dehydrogenase (LDH), D-dimer, erythrocyte sedimentation rate (ESR), C-reaction protein (CRP) and serum ferritin were significantly higher in non-complete clinical response group as compared with complete clinical response group. As for the treatment, the percentage of glucocorticoid received and intravenous immunoglobin (IVIG) were significantly higher in non-complete clinical response group than in complete clinical response group. Risk factor analysis showed that IMNM subtype (P=0.007), interstitial lung disease (ILD) (P=0.001), eleva-ted AST (P=0.012), elevated serum ferritin (P=0.016) and decreased count of CD4+T cells in peripheral blood (P=0.004) might be the risk factors for IIMs non-complete clinical response.
CONCLUSION: The total complete clinical response rate of IIMs is low, especially for IMNM subtype. More effective intervention should be administered to patients with ILD, elevated AST, elevated serum ferritin or decreased count of CD4+T cells at disease onset.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:56 |
|---|---|
| Enthalten in: |
Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences - 56(2024), 2 vom: 18. Apr., Seite 284-292 |
| Sprache: |
Chinesisch |
|---|
| Beteiligte Personen: |
Lai, Zhanhong [VerfasserIn] |
|---|
| Themen: |
Autoantibodies |
|---|
| Anmerkungen: |
Date Completed 11.04.2024 Date Revised 25.04.2024 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM370845862 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM370845862 | ||
| 003 | DE-627 | ||
| 005 | 20240425233706.0 | ||
| 007 | tu | ||
| 008 | 240410s2024 xx ||||| 00| ||chi c | ||
| 028 | 5 | 2 | |a pubmed24n1386.xml |
| 035 | |a (DE-627)NLM370845862 | ||
| 035 | |a (NLM)38595246 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a chi | ||
| 100 | 1 | |a Lai, Zhanhong |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A unicenter real-world study of the correlation factors for complete clinical response in idiopathic inflammatory myopathies |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 11.04.2024 | ||
| 500 | |a Date Revised 25.04.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a OBJECTIVE: To investigate the correlation factors of complete clinical response in idiopathic inflammatory myopathies (IIMs) patients receiving conventional treatment | ||
| 520 | |a METHODS: Patients diagnosed with IIMs hospitalized in Peking University People's Hospital from January 2000 to June 2023 were included. The correlation factors of complete clinical response to conventional treatment were identified by analyzing the clinical characteristics, laboratory features, peripheral blood lymphocytes, immunological indicators, and therapeutic drugs | ||
| 520 | |a RESULTS: Among the 635 patients included, 518 patients finished the follow-up, with an average time of 36.8 months. The total complete clinical response rate of IIMs was 50.0% (259/518). The complete clinical response rate of dermatomyositis (DM), anti-synthetase syndrome (ASS) and immune-mediated necrotizing myopathy (IMNM) were 53.5%, 48.9% and 39.0%, respectively. Fever (P=0.002) and rapid progressive interstitial lung disease (RP-ILD) (P=0.014) were observed much more frequently in non-complete clinical response group than in complete clinical response group. The aspartate transaminase (AST), lactate dehydrogenase (LDH), D-dimer, erythrocyte sedimentation rate (ESR), C-reaction protein (CRP) and serum ferritin were significantly higher in non-complete clinical response group as compared with complete clinical response group. As for the treatment, the percentage of glucocorticoid received and intravenous immunoglobin (IVIG) were significantly higher in non-complete clinical response group than in complete clinical response group. Risk factor analysis showed that IMNM subtype (P=0.007), interstitial lung disease (ILD) (P=0.001), eleva-ted AST (P=0.012), elevated serum ferritin (P=0.016) and decreased count of CD4+T cells in peripheral blood (P=0.004) might be the risk factors for IIMs non-complete clinical response | ||
| 520 | |a CONCLUSION: The total complete clinical response rate of IIMs is low, especially for IMNM subtype. More effective intervention should be administered to patients with ILD, elevated AST, elevated serum ferritin or decreased count of CD4+T cells at disease onset | ||
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Autoantibodies | |
| 650 | 4 | |a Clinical response | |
| 650 | 4 | |a Idiopathic inflammatory myopathies | |
| 650 | 4 | |a Interstitial lung disease | |
| 650 | 4 | |a Risk factors | |
| 650 | 7 | |a Autoantibodies |2 NLM | |
| 700 | 1 | |a Li, Jiachen |e verfasserin |4 aut | |
| 700 | 1 | |a Yun, Zelin |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Yonggang |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Hao |e verfasserin |4 aut | |
| 700 | 1 | |a Xing, Xiaoyan |e verfasserin |4 aut | |
| 700 | 1 | |a Shao, Miao |e verfasserin |4 aut | |
| 700 | 1 | |a Jin, Yuebo |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Naidi |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Yimin |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Yuhui |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Zhanguo |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences |d 2003 |g 56(2024), 2 vom: 18. Apr., Seite 284-292 |w (DE-627)NLM126673543 |x 1671-167X |7 nnns |
| 773 | 1 | 8 | |g volume:56 |g year:2024 |g number:2 |g day:18 |g month:04 |g pages:284-292 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 56 |j 2024 |e 2 |b 18 |c 04 |h 284-292 | ||